Medifast Framtida tillväxt
Future kriterier kontrolleras 0/6
Medifast s intäkter förväntas minska med 9.1% per år medan dess årliga intäkter förväntas växa med 106.4% per år. EPS förväntas tillväxt med 106.7% per år.
Viktig information
106.4%
Tillväxttakt i vinsten
106.70%
Tillväxttakt för EPS
| Personal Products vinsttillväxt | 27.4% |
| Intäkternas tillväxttakt | -9.1% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 04 Aug 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Seeking Alpha • Aug 06
Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)
Summary Medifast, Inc. has started to report stabilizing sales through improved coach productivity, shown again in the Q2 report. Stabilized sales provide a pathway to stabilize earnings. MED targets profitability by Q4 already, but the target has to be taken with caution. Due to MED's $15.2 in net cash per share, the stock seems attractive. I estimate 44% upside to $18.8 on the condition that earnings improve near breakeven. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jun 25
MED: Leadership Transition And Higher Future P/E Will Support Upside Potential
Analysts have modestly adjusted their price target on Medifast, reflecting updated assumptions for discount rate, revenue trends, profit margins, and a higher future P/E multiple. These factors together temper near-term earnings expectations while slightly lifting the valuation framework in dollar terms.Uppdatering av berättelse • Jun 06
MED: Leadership Transition And Margin Outlook Will Shape Balanced Future Profile
Analysts have modestly adjusted their price target on Medifast, reflecting updated views on the discount rate, expected profit margins near 8.1%, and an anticipated P/E around 9.7x, which together suggest a slightly different risk and valuation profile for the stock. What's in the News The board has appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026.Uppdatering av berättelse • May 19
MED: Insurance Reimbursement And Metabolic Health Science Will Support Balanced Outlook
Analysts have reduced their Medifast price targets to reflect updated assumptions that now indicate a slower revenue decline, improved profit margins, and a lower forward P/E. Taken together, these factors reset estimated fair value closer to $12.Uppdatering av berättelse • May 03
MED: Insurance Reimbursement And Metabolic Health Data Will Support Balanced Long-Term Outlook
Analysts have modestly adjusted their price target on Medifast, reflecting small tweaks to assumptions around the discount rate, profit margin, and future P/E, while maintaining a fair value of $12.00. These changes together point to a slightly refined view of the company’s risk and earnings outlook.Uppdatering av berättelse • Apr 18
MED: Metabolic Health Initiatives And Insurance Access Will Support Balanced Long-Term Outlook
Analyst price targets for Medifast have been reset, with updated assumptions pointing to a fair value of $12.00 per share. This is now based on a slightly higher discount rate, a similar revenue outlook, a higher profit margin and a lower forward P/E, which analysts cite as the main drivers of the change.Uppdatering av berättelse • Apr 04
MED: Future Leadership And Metabolic Health Expansion Will Support Long-Term Upside
Analysts have marginally adjusted their price target on Medifast, reflecting slightly higher assumed profit margins and a modestly higher discount rate while keeping fair value at $12. They are framing this as a fine tuning of expectations rather than a major shift in outlook.Uppdatering av berättelse • Mar 20
MED: Future Leadership Shift Will Seek To Unlock Metabolic Health Opportunity
Analysts have slightly revised their price target on Medifast, with the updated fair value holding at $12.00 as small adjustments to the discount rate and future P/E assumptions refine the underlying model rather than indicate a major change in outlook. What's in the News OPTAVIA’s comprehensive metabolic health system is now eligible for reimbursement on select insurance plans via HSA and FSA funds, which can allow some clients to use pre tax dollars toward program costs (Product related announcement).Uppdatering av berättelse • Mar 05
MED: Future Leadership Shift Will Align With New Metabolic Health System
Analysts have modestly reduced their price target on Medifast, citing a slightly lower discount rate, a small improvement in projected profit margin, and a shift to a lower future P/E assumption. Together, these factors point to a more cautious valuation framework in dollar terms.Uppdatering av berättelse • Feb 19
MED: Future Leadership Shift Will Present Long Term Opportunity
Analysts have trimmed their price target for Medifast from $15 to $12, citing updated assumptions that point to softer revenue growth, lower profit margins, and a higher future P/E multiple. What's in the News Medifast issued earnings guidance for the first quarter of 2026, projecting revenue between US$65,000,000 and US$80,000,000 and a loss per share in a range of US$0.15 to US$0.70 (company guidance).Analysartikel • Jul 03
Benign Growth For Medifast, Inc. (NYSE:MED) Underpins Its Share Price
With a price-to-sales (or "P/S") ratio of 0.3x Medifast, Inc. ( NYSE:MED ) may be sending bullish signals at the...Analysartikel • May 01
Medifast, Inc. (NYSE:MED) Just Reported, And Analysts Assigned A US$15.00 Price Target
It's been a good week for Medifast, Inc. ( NYSE:MED ) shareholders, because the company has just released its latest...Seeking Alpha • Jan 20
Medifast: Strong Balance Sheet, But I Lack Conviction In The Turnaround
Summary Medifast enjoyed record profits immediately after the pandemic. The emergence of GLP-1 medications has driven revenue, income, and the number of active Optavia coaches down. Management has laid out a strategy for Medifast to acquire customers who are taking GLP-1s, starting with a collaboration with LifeMD. With a strong balance sheet, but without enough conviction of the success of their strategy, I rate Medifast a Hold. Read the full article on Seeking AlphaAnalysartikel • Jan 09
An Intrinsic Calculation For Medifast, Inc. (NYSE:MED) Suggests It's 41% Undervalued
Key Insights Medifast's estimated fair value is US$26.41 based on 2 Stage Free Cash Flow to Equity Medifast's US$15.64...Analysartikel • Dec 11
Medifast, Inc.'s (NYSE:MED) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 0.3x Medifast, Inc. ( NYSE:MED ) is a stock worth checking...
Ny berättelse • Nov 10
GLP-1 Medication Surge And Stalling Coach Productivity Threaten Revenue Decline
The adoption of weight loss medications impacts Medifast's business model, threatening future revenue and customer acquisition.Seeking Alpha • Nov 06
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Summary Medifast reported better-than-expected quarterly EPS and is investing in new marketing strategies, AI technologies, and supply chain optimization to drive future growth. Despite a decline in the number of coaches and productivity, MED trades close to its book value and continues to generate free cash flow. The company's stock repurchase plan and significant cash reserves indicate confidence in future growth, with a potential valuation target of $78 per share. Risks include declining coach numbers, competition from GLP-1 medications, and short-selling pressures, but MED's current valuation appears undervalued. Read the full article on Seeking AlphaSeeking Alpha • Sep 03
Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Summary Medifast's collaboration with LifeMD and acquisition of LifeMD shares are expected to boost business growth and free cash flow. The company's holistic approach combining weight loss formulas, coaches, and GLP-1 medication is a significant competitive advantage. Recent investments in marketing and supply chain optimization initiatives, including the Maryland Distribution Center closure, are likely to enhance FCF margins. Despite recent lower-than-expected EPS, MED's long-term financial growth and undervaluation suggest strong future stock price potential. Read the full article on Seeking AlphaSeeking Alpha • Aug 27
Medifast Business Continues To Shrink, Stock Still Risky
Summary Medifast's stock has plummeted, with dividends still suspended and earnings and revenue are in rapid decline. Despite a strong balance sheet, Medifast faces increased competition and market volatility, leading to a shrinking business. Revenue and earnings are expected to continue declining, making the stock less attractive with higher P/E ratios. Medifast's cash generation has diminished, and the company is focusing on growth rather than dividends, making it a risky investment. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Summary Medifast is a leader in dietary weight management that fell off a cliff since 2022 due to inflationary pressures, the re-opening of restaurants, and the rise of GLP-1 drugs. The company's turnaround plan aims to combine OPTAVIA offerings with direct access to GLP-1 medication through a partnership with LifeMD. At about $20 per share, Medifast may be in deep value territory, but strong negative momentum and the lack of turnaround proof points make it a HOLD at this time. Investors who seek long exposure with an increased margin of safety could consider selling $12.50 MED puts, noting that the company holds over $14 of net cash per share. Read the full article on Seeking AlphaSeeking Alpha • May 24
Medifast: Significant Undervaluation Even As Struggles Persist
Summary Medifast's financial performance is deteriorating rapidly due to the emergence of drug-weight loss competitors. The company reported a significant decline in revenue and earnings in Q1 2023. Medifast is laying off employees and may need to further reduce its workforce to match the revenue drop. My valuation analysis suggests that the stock is significantly undervalued, but I consider this fair given all the challenges. Read the full article on Seeking AlphaAnalysartikel • May 24
At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Medifast, Inc. ( NYSE:MED ), might not be a large cap stock, but it received a lot of attention from a substantial...Analysartikel • May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
To the annoyance of some shareholders, Medifast, Inc. ( NYSE:MED ) shares are down a considerable 32% in the last...Analysartikel • May 06
Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
Medifast, Inc.'s ( NYSE:MED ) earnings announcement last week didn't impress shareholders. While the headline numbers...Analysartikel • May 01
The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2027 | 274 | -3 | 12 | N/A | 1 |
| 12/31/2026 | 288 | -10 | -3 | N/A | 1 |
| 6/30/2026 | 317 | -26 | 4 | 9 | N/A |
| 3/31/2026 | 346 | -20 | -1 | 4 | N/A |
| 12/31/2025 | 386 | -19 | 1 | 7 | N/A |
| 9/30/2025 | 430 | 0 | 1 | 7 | N/A |
| 6/30/2025 | 480 | 4 | -2 | 4 | N/A |
| 3/31/2025 | 543 | -7 | 13 | 21 | N/A |
| 12/31/2024 | 602 | 2 | 17 | 24 | N/A |
| 9/30/2024 | 674 | 7 | 34 | 40 | N/A |
| 6/30/2024 | 770 | 29 | 54 | 61 | N/A |
| 3/31/2024 | 898 | 68 | 85 | 91 | N/A |
| 12/31/2023 | 1,072 | 99 | 141 | 148 | N/A |
| 9/30/2023 | 1,218 | 120 | 174 | 189 | N/A |
| 6/30/2023 | 1,373 | 133 | 200 | 214 | N/A |
| 3/31/2023 | 1,530 | 142 | 199 | 215 | N/A |
| 12/31/2022 | 1,599 | 144 | 178 | 195 | N/A |
| 9/30/2022 | 1,639 | 151 | 116 | 135 | N/A |
| 6/30/2022 | 1,662 | 157 | 68 | 96 | N/A |
| 3/31/2022 | 1,603 | 165 | 40 | 73 | N/A |
| 12/31/2021 | 1,526 | 164 | 60 | 95 | N/A |
| 9/30/2021 | 1,413 | 158 | 97 | 122 | N/A |
| 6/30/2021 | 1,271 | 150 | 130 | 147 | N/A |
| 3/31/2021 | 1,097 | 125 | 174 | 184 | N/A |
| 12/31/2020 | 935 | 103 | 139 | 145 | N/A |
| 9/30/2020 | 841 | 95 | 140 | 145 | N/A |
| 6/30/2020 | 759 | 76 | 118 | 121 | N/A |
| 3/31/2020 | 726 | 76 | N/A | 78 | N/A |
| 12/31/2019 | 714 | 78 | N/A | 84 | N/A |
| 9/30/2019 | 689 | 74 | N/A | 80 | N/A |
| 6/30/2019 | 638 | 72 | N/A | 69 | N/A |
| 3/31/2019 | 568 | 64 | N/A | 76 | N/A |
| 12/31/2018 | 501 | 56 | N/A | 61 | N/A |
| 9/30/2018 | 433 | 47 | N/A | 55 | N/A |
| 6/30/2018 | 371 | 40 | N/A | 61 | N/A |
| 3/31/2018 | 330 | 34 | N/A | 55 | N/A |
| 12/31/2017 | 302 | 28 | N/A | 43 | N/A |
| 9/30/2017 | 286 | 25 | N/A | 33 | N/A |
| 6/30/2017 | 277 | 24 | N/A | 27 | N/A |
| 3/31/2017 | 273 | 20 | N/A | 24 | N/A |
| 12/31/2016 | 275 | 18 | N/A | 25 | N/A |
| 9/30/2016 | 273 | 18 | N/A | 28 | N/A |
| 6/30/2016 | 271 | 17 | N/A | 30 | N/A |
| 3/31/2016 | 272 | 19 | N/A | 27 | N/A |
| 12/31/2015 | 273 | 20 | N/A | 29 | N/A |
| 9/30/2015 | 274 | 18 | N/A | 28 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: MED förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: MED förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: MED förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: MED s intäkter förväntas minska under de kommande 3 åren ( -9.1% per år).
Hög tillväxtintäkter: MED s intäkter förväntas minska under de kommande 3 åren ( -9.1% per år).
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om MED s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/13 17:43 |
| Aktiekurs vid dagens slut | 2026/09/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Medifast, Inc. bevakas av 8 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| John San Marco | Brean Capital Historical (Janney Montgomery) |
| Kara Anderson | B. Riley Securities, Inc. |
| Scott Van Winkle | Canaccord Genuity |